Cardiomyopathy and Stem Cells

Cardiomyopathy is a disease of the heart muscle that can lead to heart failure. In the United States, about one in every 250 adults has cardiomyopathy, which is the leading cause of heart failure. There are many different types of cardiomyopathy, but the most common type is dilated cardiomyopathy. This type is characterized by an enlarged heart and thinning of the heart muscle. Dilated cardiomyopathy is often caused by coronary artery disease, high blood pressure, diabetes, or a viral infection. The good news is that stem cell therapy is a promising treatment for cardiomyopathy. Stem cells are special cells that have the ability to develop into any type of cell in the body. This means that they can be used to replace damaged heart muscle cells. In a small study of patients with dilated cardiomyopathy, stem cell therapy was found to improve heart function and reduce the size of the heart. The study was published in the journal Circulation in 2012. In another study, stem cell therapy was found to be safe and effective in treating patients with non-ischemic cardiomyopathy. The study was published in the New England Journal of Medicine in 2015. Stem cell therapy is still in the early stages of research, and more studies are needed to determine its long-term safety and effectiveness. However, the results of these studies are very promising and suggest that stem cell therapy may one day be used to treat cardiomyopathy and other heart diseases.

 "Stem cell therapy in heart failure: Where do we stand today? - PubMed." 1 Apr. 2020, Accessed 24 Oct. 2022.

 "Effects of stem cell therapy on dilated cardiomyopathy - PMC - NCBI." Accessed 24 Oct. 2022.

 "Stem cell therapy for heart failure reduced major CV events and ...." 14 Nov. 2021, Accessed 24 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
Myers cocktail/NAD50,000,0001N/A